Platelet Activating Factor (PAF)

Summary This review is an attempt to summarise recent data on platelet activating factor (PAF) and PAF antagonists from 1988 to the present. This period saw a burst in research activity focused predominantly on the effect of PAF in various organs. The effect of PAF and its antagonists was further intensively studied in vitro on isolated platelets, leucocytes, macrophages and endothelial cells. From these and earlier data, based on the catastrophe theory of Thorn and Zeeman, a new concept on the interaction between PAF and various cytokines could be recognised as an important mechanism of action of the phospholipid mediator, suggesting the existence of an autocatalytic feedback network through which PAF can influence cellular function under certain pathophysiological conditions. This mechanism can be regarded as the culmination of our recent knowledge on the role of PAF, and may influence the possible clinical implications of PAF antagonists in the near future. It is recognised that PAF is released in shock and ischaemic states, and that PAF antagonists can protect the heart and brain against ischaemic injury. Therefore, in contrast to the previous period, which was predominantly devoted to the elucidation of the role of PAF in immediate hypersensitivity reactions, studies performed on cerebral, myocardial and intestinal ischaemia as well as in various shock conditions have concentrated on entirely new aspects of the effect of PAF antagonists, emphasising the significance of the inflammatory process and cell-to-cell interactions in these pathophysiological states. This has led to a re-evaluation of the experimental data previously accumulated. At the same time, these new trends in PAF and PAF antagonist research have explored further possibilities for the application of PAF antagonists in clinical practice. Attention has been focused on the physiological role of PAF as a signal molecule, especially between the neuroendocrine system and related sensory organs. The recognition of the significance of PAF in mammalian reproduction is fascinating and may lead to new clinical applications of PAF antagonists. It appears probable that, like eicosanoids, PAF is involved in a great variety of membrane-dependent processes that play a fundamental role in the maintenance of homeostasis. PAF research has provided several potent natural and synthetic antagonists which may facilitate the clinical application of these drugs in the near future. Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Koltai, Matyas [verfasserIn] Hosford, David [verfasserIn] Guinot, Philippe [verfasserIn] Esanu, André [verfasserIn] Braquet, Pierre [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	1991

Schlagwörter:	Platelet Activate Factor Rabbit Platelet Platelet Activate Factor Receptor Platelet Activate Factor Antagonist Tumour Necrosis Factor Secretion

Übergeordnetes Werk:	Enthalten in: Drugs - Berlin [u.a.] : Springer, 1971, 42(1991), 1 vom: Juli, Seite 9-29
Übergeordnetes Werk:	volume:42 ; year:1991 ; number:1 ; month:07 ; pages:9-29

Links:	Volltext

DOI / URN:	10.2165/00003495-199142010-00002

Katalog-ID:	SPR033158266

Internformat


LEADER	01000caa a22002652 4500
001	SPR033158266
003	DE-627
005	20230519202325.0
007	cr uuu---uuuuu
008	201007s1991 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.2165/00003495-199142010-00002 \|2 doi
035			\|a (DE-627)SPR033158266
035			\|a (SPR)00003495-199142010-00002-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q ASE
084			\|a 44.40 \|2 bkl
084			\|a 44.38 \|2 bkl
100	1		\|a Koltai, Matyas \|e verfasserin \|4 aut
245	1	0	\|a Platelet Activating Factor (PAF)
264		1	\|c 1991
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Summary This review is an attempt to summarise recent data on platelet activating factor (PAF) and PAF antagonists from 1988 to the present. This period saw a burst in research activity focused predominantly on the effect of PAF in various organs. The effect of PAF and its antagonists was further intensively studied in vitro on isolated platelets, leucocytes, macrophages and endothelial cells. From these and earlier data, based on the catastrophe theory of Thorn and Zeeman, a new concept on the interaction between PAF and various cytokines could be recognised as an important mechanism of action of the phospholipid mediator, suggesting the existence of an autocatalytic feedback network through which PAF can influence cellular function under certain pathophysiological conditions. This mechanism can be regarded as the culmination of our recent knowledge on the role of PAF, and may influence the possible clinical implications of PAF antagonists in the near future. It is recognised that PAF is released in shock and ischaemic states, and that PAF antagonists can protect the heart and brain against ischaemic injury. Therefore, in contrast to the previous period, which was predominantly devoted to the elucidation of the role of PAF in immediate hypersensitivity reactions, studies performed on cerebral, myocardial and intestinal ischaemia as well as in various shock conditions have concentrated on entirely new aspects of the effect of PAF antagonists, emphasising the significance of the inflammatory process and cell-to-cell interactions in these pathophysiological states. This has led to a re-evaluation of the experimental data previously accumulated. At the same time, these new trends in PAF and PAF antagonist research have explored further possibilities for the application of PAF antagonists in clinical practice. Attention has been focused on the physiological role of PAF as a signal molecule, especially between the neuroendocrine system and related sensory organs. The recognition of the significance of PAF in mammalian reproduction is fascinating and may lead to new clinical applications of PAF antagonists. It appears probable that, like eicosanoids, PAF is involved in a great variety of membrane-dependent processes that play a fundamental role in the maintenance of homeostasis. PAF research has provided several potent natural and synthetic antagonists which may facilitate the clinical application of these drugs in the near future.
650		4	\|a Platelet Activate Factor \|7 (dpeaa)DE-He213
650		4	\|a Rabbit Platelet \|7 (dpeaa)DE-He213
650		4	\|a Platelet Activate Factor Receptor \|7 (dpeaa)DE-He213
650		4	\|a Platelet Activate Factor Antagonist \|7 (dpeaa)DE-He213
650		4	\|a Tumour Necrosis Factor Secretion \|7 (dpeaa)DE-He213
700	1		\|a Hosford, David \|e verfasserin \|4 aut
700	1		\|a Guinot, Philippe \|e verfasserin \|4 aut
700	1		\|a Esanu, André \|e verfasserin \|4 aut
700	1		\|a Braquet, Pierre \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Drugs \|d Berlin [u.a.] : Springer, 1971 \|g 42(1991), 1 vom: Juli, Seite 9-29 \|w (DE-627)320609413 \|w (DE-600)2021165-X \|x 1179-1950 \|7 nnns
773	1	8	\|g volume:42 \|g year:1991 \|g number:1 \|g month:07 \|g pages:9-29
856	4	0	\|u https://dx.doi.org/10.2165/00003495-199142010-00002 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a SSG-OPC-PHA
912			\|a SSG-OPC-ASE
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2190
936	b	k	\|a 44.40 \|q ASE
936	b	k	\|a 44.38 \|q ASE
951			\|a AR
952			\|d 42 \|j 1991 \|e 1 \|c 07 \|h 9-29

Indexfelder

author_variant	m k mk d h dh p g pg a e ae p b pb
matchkey_str	article:11791950:1991----::ltltciaig
hierarchy_sort_str	1991
bklnumber	44.40 44.38
publishDate	1991
allfields	10.2165/00003495-199142010-00002 doi (DE-627)SPR033158266 (SPR)00003495-199142010-00002-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl 44.38 bkl Koltai, Matyas verfasserin aut Platelet Activating Factor (PAF) 1991 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary This review is an attempt to summarise recent data on platelet activating factor (PAF) and PAF antagonists from 1988 to the present. This period saw a burst in research activity focused predominantly on the effect of PAF in various organs. The effect of PAF and its antagonists was further intensively studied in vitro on isolated platelets, leucocytes, macrophages and endothelial cells. From these and earlier data, based on the catastrophe theory of Thorn and Zeeman, a new concept on the interaction between PAF and various cytokines could be recognised as an important mechanism of action of the phospholipid mediator, suggesting the existence of an autocatalytic feedback network through which PAF can influence cellular function under certain pathophysiological conditions. This mechanism can be regarded as the culmination of our recent knowledge on the role of PAF, and may influence the possible clinical implications of PAF antagonists in the near future. It is recognised that PAF is released in shock and ischaemic states, and that PAF antagonists can protect the heart and brain against ischaemic injury. Therefore, in contrast to the previous period, which was predominantly devoted to the elucidation of the role of PAF in immediate hypersensitivity reactions, studies performed on cerebral, myocardial and intestinal ischaemia as well as in various shock conditions have concentrated on entirely new aspects of the effect of PAF antagonists, emphasising the significance of the inflammatory process and cell-to-cell interactions in these pathophysiological states. This has led to a re-evaluation of the experimental data previously accumulated. At the same time, these new trends in PAF and PAF antagonist research have explored further possibilities for the application of PAF antagonists in clinical practice. Attention has been focused on the physiological role of PAF as a signal molecule, especially between the neuroendocrine system and related sensory organs. The recognition of the significance of PAF in mammalian reproduction is fascinating and may lead to new clinical applications of PAF antagonists. It appears probable that, like eicosanoids, PAF is involved in a great variety of membrane-dependent processes that play a fundamental role in the maintenance of homeostasis. PAF research has provided several potent natural and synthetic antagonists which may facilitate the clinical application of these drugs in the near future. Platelet Activate Factor (dpeaa)DE-He213 Rabbit Platelet (dpeaa)DE-He213 Platelet Activate Factor Receptor (dpeaa)DE-He213 Platelet Activate Factor Antagonist (dpeaa)DE-He213 Tumour Necrosis Factor Secretion (dpeaa)DE-He213 Hosford, David verfasserin aut Guinot, Philippe verfasserin aut Esanu, André verfasserin aut Braquet, Pierre verfasserin aut Enthalten in Drugs Berlin [u.a.] : Springer, 1971 42(1991), 1 vom: Juli, Seite 9-29 (DE-627)320609413 (DE-600)2021165-X 1179-1950 nnns volume:42 year:1991 number:1 month:07 pages:9-29 https://dx.doi.org/10.2165/00003495-199142010-00002 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE 44.38 ASE AR 42 1991 1 07 9-29
spelling	10.2165/00003495-199142010-00002 doi (DE-627)SPR033158266 (SPR)00003495-199142010-00002-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl 44.38 bkl Koltai, Matyas verfasserin aut Platelet Activating Factor (PAF) 1991 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary This review is an attempt to summarise recent data on platelet activating factor (PAF) and PAF antagonists from 1988 to the present. This period saw a burst in research activity focused predominantly on the effect of PAF in various organs. The effect of PAF and its antagonists was further intensively studied in vitro on isolated platelets, leucocytes, macrophages and endothelial cells. From these and earlier data, based on the catastrophe theory of Thorn and Zeeman, a new concept on the interaction between PAF and various cytokines could be recognised as an important mechanism of action of the phospholipid mediator, suggesting the existence of an autocatalytic feedback network through which PAF can influence cellular function under certain pathophysiological conditions. This mechanism can be regarded as the culmination of our recent knowledge on the role of PAF, and may influence the possible clinical implications of PAF antagonists in the near future. It is recognised that PAF is released in shock and ischaemic states, and that PAF antagonists can protect the heart and brain against ischaemic injury. Therefore, in contrast to the previous period, which was predominantly devoted to the elucidation of the role of PAF in immediate hypersensitivity reactions, studies performed on cerebral, myocardial and intestinal ischaemia as well as in various shock conditions have concentrated on entirely new aspects of the effect of PAF antagonists, emphasising the significance of the inflammatory process and cell-to-cell interactions in these pathophysiological states. This has led to a re-evaluation of the experimental data previously accumulated. At the same time, these new trends in PAF and PAF antagonist research have explored further possibilities for the application of PAF antagonists in clinical practice. Attention has been focused on the physiological role of PAF as a signal molecule, especially between the neuroendocrine system and related sensory organs. The recognition of the significance of PAF in mammalian reproduction is fascinating and may lead to new clinical applications of PAF antagonists. It appears probable that, like eicosanoids, PAF is involved in a great variety of membrane-dependent processes that play a fundamental role in the maintenance of homeostasis. PAF research has provided several potent natural and synthetic antagonists which may facilitate the clinical application of these drugs in the near future. Platelet Activate Factor (dpeaa)DE-He213 Rabbit Platelet (dpeaa)DE-He213 Platelet Activate Factor Receptor (dpeaa)DE-He213 Platelet Activate Factor Antagonist (dpeaa)DE-He213 Tumour Necrosis Factor Secretion (dpeaa)DE-He213 Hosford, David verfasserin aut Guinot, Philippe verfasserin aut Esanu, André verfasserin aut Braquet, Pierre verfasserin aut Enthalten in Drugs Berlin [u.a.] : Springer, 1971 42(1991), 1 vom: Juli, Seite 9-29 (DE-627)320609413 (DE-600)2021165-X 1179-1950 nnns volume:42 year:1991 number:1 month:07 pages:9-29 https://dx.doi.org/10.2165/00003495-199142010-00002 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE 44.38 ASE AR 42 1991 1 07 9-29
allfields_unstemmed	10.2165/00003495-199142010-00002 doi (DE-627)SPR033158266 (SPR)00003495-199142010-00002-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl 44.38 bkl Koltai, Matyas verfasserin aut Platelet Activating Factor (PAF) 1991 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary This review is an attempt to summarise recent data on platelet activating factor (PAF) and PAF antagonists from 1988 to the present. This period saw a burst in research activity focused predominantly on the effect of PAF in various organs. The effect of PAF and its antagonists was further intensively studied in vitro on isolated platelets, leucocytes, macrophages and endothelial cells. From these and earlier data, based on the catastrophe theory of Thorn and Zeeman, a new concept on the interaction between PAF and various cytokines could be recognised as an important mechanism of action of the phospholipid mediator, suggesting the existence of an autocatalytic feedback network through which PAF can influence cellular function under certain pathophysiological conditions. This mechanism can be regarded as the culmination of our recent knowledge on the role of PAF, and may influence the possible clinical implications of PAF antagonists in the near future. It is recognised that PAF is released in shock and ischaemic states, and that PAF antagonists can protect the heart and brain against ischaemic injury. Therefore, in contrast to the previous period, which was predominantly devoted to the elucidation of the role of PAF in immediate hypersensitivity reactions, studies performed on cerebral, myocardial and intestinal ischaemia as well as in various shock conditions have concentrated on entirely new aspects of the effect of PAF antagonists, emphasising the significance of the inflammatory process and cell-to-cell interactions in these pathophysiological states. This has led to a re-evaluation of the experimental data previously accumulated. At the same time, these new trends in PAF and PAF antagonist research have explored further possibilities for the application of PAF antagonists in clinical practice. Attention has been focused on the physiological role of PAF as a signal molecule, especially between the neuroendocrine system and related sensory organs. The recognition of the significance of PAF in mammalian reproduction is fascinating and may lead to new clinical applications of PAF antagonists. It appears probable that, like eicosanoids, PAF is involved in a great variety of membrane-dependent processes that play a fundamental role in the maintenance of homeostasis. PAF research has provided several potent natural and synthetic antagonists which may facilitate the clinical application of these drugs in the near future. Platelet Activate Factor (dpeaa)DE-He213 Rabbit Platelet (dpeaa)DE-He213 Platelet Activate Factor Receptor (dpeaa)DE-He213 Platelet Activate Factor Antagonist (dpeaa)DE-He213 Tumour Necrosis Factor Secretion (dpeaa)DE-He213 Hosford, David verfasserin aut Guinot, Philippe verfasserin aut Esanu, André verfasserin aut Braquet, Pierre verfasserin aut Enthalten in Drugs Berlin [u.a.] : Springer, 1971 42(1991), 1 vom: Juli, Seite 9-29 (DE-627)320609413 (DE-600)2021165-X 1179-1950 nnns volume:42 year:1991 number:1 month:07 pages:9-29 https://dx.doi.org/10.2165/00003495-199142010-00002 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE 44.38 ASE AR 42 1991 1 07 9-29
allfieldsGer	10.2165/00003495-199142010-00002 doi (DE-627)SPR033158266 (SPR)00003495-199142010-00002-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl 44.38 bkl Koltai, Matyas verfasserin aut Platelet Activating Factor (PAF) 1991 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary This review is an attempt to summarise recent data on platelet activating factor (PAF) and PAF antagonists from 1988 to the present. This period saw a burst in research activity focused predominantly on the effect of PAF in various organs. The effect of PAF and its antagonists was further intensively studied in vitro on isolated platelets, leucocytes, macrophages and endothelial cells. From these and earlier data, based on the catastrophe theory of Thorn and Zeeman, a new concept on the interaction between PAF and various cytokines could be recognised as an important mechanism of action of the phospholipid mediator, suggesting the existence of an autocatalytic feedback network through which PAF can influence cellular function under certain pathophysiological conditions. This mechanism can be regarded as the culmination of our recent knowledge on the role of PAF, and may influence the possible clinical implications of PAF antagonists in the near future. It is recognised that PAF is released in shock and ischaemic states, and that PAF antagonists can protect the heart and brain against ischaemic injury. Therefore, in contrast to the previous period, which was predominantly devoted to the elucidation of the role of PAF in immediate hypersensitivity reactions, studies performed on cerebral, myocardial and intestinal ischaemia as well as in various shock conditions have concentrated on entirely new aspects of the effect of PAF antagonists, emphasising the significance of the inflammatory process and cell-to-cell interactions in these pathophysiological states. This has led to a re-evaluation of the experimental data previously accumulated. At the same time, these new trends in PAF and PAF antagonist research have explored further possibilities for the application of PAF antagonists in clinical practice. Attention has been focused on the physiological role of PAF as a signal molecule, especially between the neuroendocrine system and related sensory organs. The recognition of the significance of PAF in mammalian reproduction is fascinating and may lead to new clinical applications of PAF antagonists. It appears probable that, like eicosanoids, PAF is involved in a great variety of membrane-dependent processes that play a fundamental role in the maintenance of homeostasis. PAF research has provided several potent natural and synthetic antagonists which may facilitate the clinical application of these drugs in the near future. Platelet Activate Factor (dpeaa)DE-He213 Rabbit Platelet (dpeaa)DE-He213 Platelet Activate Factor Receptor (dpeaa)DE-He213 Platelet Activate Factor Antagonist (dpeaa)DE-He213 Tumour Necrosis Factor Secretion (dpeaa)DE-He213 Hosford, David verfasserin aut Guinot, Philippe verfasserin aut Esanu, André verfasserin aut Braquet, Pierre verfasserin aut Enthalten in Drugs Berlin [u.a.] : Springer, 1971 42(1991), 1 vom: Juli, Seite 9-29 (DE-627)320609413 (DE-600)2021165-X 1179-1950 nnns volume:42 year:1991 number:1 month:07 pages:9-29 https://dx.doi.org/10.2165/00003495-199142010-00002 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE 44.38 ASE AR 42 1991 1 07 9-29
allfieldsSound	10.2165/00003495-199142010-00002 doi (DE-627)SPR033158266 (SPR)00003495-199142010-00002-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl 44.38 bkl Koltai, Matyas verfasserin aut Platelet Activating Factor (PAF) 1991 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary This review is an attempt to summarise recent data on platelet activating factor (PAF) and PAF antagonists from 1988 to the present. This period saw a burst in research activity focused predominantly on the effect of PAF in various organs. The effect of PAF and its antagonists was further intensively studied in vitro on isolated platelets, leucocytes, macrophages and endothelial cells. From these and earlier data, based on the catastrophe theory of Thorn and Zeeman, a new concept on the interaction between PAF and various cytokines could be recognised as an important mechanism of action of the phospholipid mediator, suggesting the existence of an autocatalytic feedback network through which PAF can influence cellular function under certain pathophysiological conditions. This mechanism can be regarded as the culmination of our recent knowledge on the role of PAF, and may influence the possible clinical implications of PAF antagonists in the near future. It is recognised that PAF is released in shock and ischaemic states, and that PAF antagonists can protect the heart and brain against ischaemic injury. Therefore, in contrast to the previous period, which was predominantly devoted to the elucidation of the role of PAF in immediate hypersensitivity reactions, studies performed on cerebral, myocardial and intestinal ischaemia as well as in various shock conditions have concentrated on entirely new aspects of the effect of PAF antagonists, emphasising the significance of the inflammatory process and cell-to-cell interactions in these pathophysiological states. This has led to a re-evaluation of the experimental data previously accumulated. At the same time, these new trends in PAF and PAF antagonist research have explored further possibilities for the application of PAF antagonists in clinical practice. Attention has been focused on the physiological role of PAF as a signal molecule, especially between the neuroendocrine system and related sensory organs. The recognition of the significance of PAF in mammalian reproduction is fascinating and may lead to new clinical applications of PAF antagonists. It appears probable that, like eicosanoids, PAF is involved in a great variety of membrane-dependent processes that play a fundamental role in the maintenance of homeostasis. PAF research has provided several potent natural and synthetic antagonists which may facilitate the clinical application of these drugs in the near future. Platelet Activate Factor (dpeaa)DE-He213 Rabbit Platelet (dpeaa)DE-He213 Platelet Activate Factor Receptor (dpeaa)DE-He213 Platelet Activate Factor Antagonist (dpeaa)DE-He213 Tumour Necrosis Factor Secretion (dpeaa)DE-He213 Hosford, David verfasserin aut Guinot, Philippe verfasserin aut Esanu, André verfasserin aut Braquet, Pierre verfasserin aut Enthalten in Drugs Berlin [u.a.] : Springer, 1971 42(1991), 1 vom: Juli, Seite 9-29 (DE-627)320609413 (DE-600)2021165-X 1179-1950 nnns volume:42 year:1991 number:1 month:07 pages:9-29 https://dx.doi.org/10.2165/00003495-199142010-00002 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE 44.38 ASE AR 42 1991 1 07 9-29
language	English
source	Enthalten in Drugs 42(1991), 1 vom: Juli, Seite 9-29 volume:42 year:1991 number:1 month:07 pages:9-29
sourceStr	Enthalten in Drugs 42(1991), 1 vom: Juli, Seite 9-29 volume:42 year:1991 number:1 month:07 pages:9-29
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Platelet Activate Factor Rabbit Platelet Platelet Activate Factor Receptor Platelet Activate Factor Antagonist Tumour Necrosis Factor Secretion
dewey-raw	610
isfreeaccess_bool	false
container_title	Drugs
authorswithroles_txt_mv	Koltai, Matyas @@aut@@ Hosford, David @@aut@@ Guinot, Philippe @@aut@@ Esanu, André @@aut@@ Braquet, Pierre @@aut@@
publishDateDaySort_date	1991-07-01T00:00:00Z
hierarchy_top_id	320609413
dewey-sort	3610
id	SPR033158266
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033158266</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519202325.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1991 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00003495-199142010-00002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033158266</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00003495-199142010-00002-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.38</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Koltai, Matyas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Platelet Activating Factor (PAF)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1991</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary This review is an attempt to summarise recent data on platelet activating factor (PAF) and PAF antagonists from 1988 to the present. This period saw a burst in research activity focused predominantly on the effect of PAF in various organs. The effect of PAF and its antagonists was further intensively studied in vitro on isolated platelets, leucocytes, macrophages and endothelial cells. From these and earlier data, based on the catastrophe theory of Thorn and Zeeman, a new concept on the interaction between PAF and various cytokines could be recognised as an important mechanism of action of the phospholipid mediator, suggesting the existence of an autocatalytic feedback network through which PAF can influence cellular function under certain pathophysiological conditions. This mechanism can be regarded as the culmination of our recent knowledge on the role of PAF, and may influence the possible clinical implications of PAF antagonists in the near future. It is recognised that PAF is released in shock and ischaemic states, and that PAF antagonists can protect the heart and brain against ischaemic injury. Therefore, in contrast to the previous period, which was predominantly devoted to the elucidation of the role of PAF in immediate hypersensitivity reactions, studies performed on cerebral, myocardial and intestinal ischaemia as well as in various shock conditions have concentrated on entirely new aspects of the effect of PAF antagonists, emphasising the significance of the inflammatory process and cell-to-cell interactions in these pathophysiological states. This has led to a re-evaluation of the experimental data previously accumulated. At the same time, these new trends in PAF and PAF antagonist research have explored further possibilities for the application of PAF antagonists in clinical practice. Attention has been focused on the physiological role of PAF as a signal molecule, especially between the neuroendocrine system and related sensory organs. The recognition of the significance of PAF in mammalian reproduction is fascinating and may lead to new clinical applications of PAF antagonists. It appears probable that, like eicosanoids, PAF is involved in a great variety of membrane-dependent processes that play a fundamental role in the maintenance of homeostasis. PAF research has provided several potent natural and synthetic antagonists which may facilitate the clinical application of these drugs in the near future.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Platelet Activate Factor</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rabbit Platelet</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Platelet Activate Factor Receptor</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Platelet Activate Factor Antagonist</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tumour Necrosis Factor Secretion</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hosford, David</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guinot, Philippe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Esanu, André</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Braquet, Pierre</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Drugs</subfield><subfield code="d">Berlin [u.a.] : Springer, 1971</subfield><subfield code="g">42(1991), 1 vom: Juli, Seite 9-29</subfield><subfield code="w">(DE-627)320609413</subfield><subfield code="w">(DE-600)2021165-X</subfield><subfield code="x">1179-1950</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:42</subfield><subfield code="g">year:1991</subfield><subfield code="g">number:1</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:9-29</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00003495-199142010-00002</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.38</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">42</subfield><subfield code="j">1991</subfield><subfield code="e">1</subfield><subfield code="c">07</subfield><subfield code="h">9-29</subfield></datafield></record></collection>
author	Koltai, Matyas
spellingShingle	Koltai, Matyas ddc 610 bkl 44.40 bkl 44.38 misc Platelet Activate Factor misc Rabbit Platelet misc Platelet Activate Factor Receptor misc Platelet Activate Factor Antagonist misc Tumour Necrosis Factor Secretion Platelet Activating Factor (PAF)
authorStr	Koltai, Matyas
ppnlink_with_tag_str_mv	@@773@@(DE-627)320609413
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1179-1950
topic_title	610 ASE 44.40 bkl 44.38 bkl Platelet Activating Factor (PAF) Platelet Activate Factor (dpeaa)DE-He213 Rabbit Platelet (dpeaa)DE-He213 Platelet Activate Factor Receptor (dpeaa)DE-He213 Platelet Activate Factor Antagonist (dpeaa)DE-He213 Tumour Necrosis Factor Secretion (dpeaa)DE-He213
topic	ddc 610 bkl 44.40 bkl 44.38 misc Platelet Activate Factor misc Rabbit Platelet misc Platelet Activate Factor Receptor misc Platelet Activate Factor Antagonist misc Tumour Necrosis Factor Secretion
topic_unstemmed	ddc 610 bkl 44.40 bkl 44.38 misc Platelet Activate Factor misc Rabbit Platelet misc Platelet Activate Factor Receptor misc Platelet Activate Factor Antagonist misc Tumour Necrosis Factor Secretion
topic_browse	ddc 610 bkl 44.40 bkl 44.38 misc Platelet Activate Factor misc Rabbit Platelet misc Platelet Activate Factor Receptor misc Platelet Activate Factor Antagonist misc Tumour Necrosis Factor Secretion
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Drugs
hierarchy_parent_id	320609413
dewey-tens	610 - Medicine & health
hierarchy_top_title	Drugs
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)320609413 (DE-600)2021165-X
title	Platelet Activating Factor (PAF)
ctrlnum	(DE-627)SPR033158266 (SPR)00003495-199142010-00002-e
title_full	Platelet Activating Factor (PAF)
author_sort	Koltai, Matyas
journal	Drugs
journalStr	Drugs
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	1991
contenttype_str_mv	txt
container_start_page	9
author_browse	Koltai, Matyas Hosford, David Guinot, Philippe Esanu, André Braquet, Pierre
container_volume	42
class	610 ASE 44.40 bkl 44.38 bkl
format_se	Elektronische Aufsätze
author-letter	Koltai, Matyas
doi_str_mv	10.2165/00003495-199142010-00002
dewey-full	610
author2-role	verfasserin
title_sort	platelet activating factor (paf)
title_auth	Platelet Activating Factor (PAF)
abstract	Summary This review is an attempt to summarise recent data on platelet activating factor (PAF) and PAF antagonists from 1988 to the present. This period saw a burst in research activity focused predominantly on the effect of PAF in various organs. The effect of PAF and its antagonists was further intensively studied in vitro on isolated platelets, leucocytes, macrophages and endothelial cells. From these and earlier data, based on the catastrophe theory of Thorn and Zeeman, a new concept on the interaction between PAF and various cytokines could be recognised as an important mechanism of action of the phospholipid mediator, suggesting the existence of an autocatalytic feedback network through which PAF can influence cellular function under certain pathophysiological conditions. This mechanism can be regarded as the culmination of our recent knowledge on the role of PAF, and may influence the possible clinical implications of PAF antagonists in the near future. It is recognised that PAF is released in shock and ischaemic states, and that PAF antagonists can protect the heart and brain against ischaemic injury. Therefore, in contrast to the previous period, which was predominantly devoted to the elucidation of the role of PAF in immediate hypersensitivity reactions, studies performed on cerebral, myocardial and intestinal ischaemia as well as in various shock conditions have concentrated on entirely new aspects of the effect of PAF antagonists, emphasising the significance of the inflammatory process and cell-to-cell interactions in these pathophysiological states. This has led to a re-evaluation of the experimental data previously accumulated. At the same time, these new trends in PAF and PAF antagonist research have explored further possibilities for the application of PAF antagonists in clinical practice. Attention has been focused on the physiological role of PAF as a signal molecule, especially between the neuroendocrine system and related sensory organs. The recognition of the significance of PAF in mammalian reproduction is fascinating and may lead to new clinical applications of PAF antagonists. It appears probable that, like eicosanoids, PAF is involved in a great variety of membrane-dependent processes that play a fundamental role in the maintenance of homeostasis. PAF research has provided several potent natural and synthetic antagonists which may facilitate the clinical application of these drugs in the near future.
abstractGer	Summary This review is an attempt to summarise recent data on platelet activating factor (PAF) and PAF antagonists from 1988 to the present. This period saw a burst in research activity focused predominantly on the effect of PAF in various organs. The effect of PAF and its antagonists was further intensively studied in vitro on isolated platelets, leucocytes, macrophages and endothelial cells. From these and earlier data, based on the catastrophe theory of Thorn and Zeeman, a new concept on the interaction between PAF and various cytokines could be recognised as an important mechanism of action of the phospholipid mediator, suggesting the existence of an autocatalytic feedback network through which PAF can influence cellular function under certain pathophysiological conditions. This mechanism can be regarded as the culmination of our recent knowledge on the role of PAF, and may influence the possible clinical implications of PAF antagonists in the near future. It is recognised that PAF is released in shock and ischaemic states, and that PAF antagonists can protect the heart and brain against ischaemic injury. Therefore, in contrast to the previous period, which was predominantly devoted to the elucidation of the role of PAF in immediate hypersensitivity reactions, studies performed on cerebral, myocardial and intestinal ischaemia as well as in various shock conditions have concentrated on entirely new aspects of the effect of PAF antagonists, emphasising the significance of the inflammatory process and cell-to-cell interactions in these pathophysiological states. This has led to a re-evaluation of the experimental data previously accumulated. At the same time, these new trends in PAF and PAF antagonist research have explored further possibilities for the application of PAF antagonists in clinical practice. Attention has been focused on the physiological role of PAF as a signal molecule, especially between the neuroendocrine system and related sensory organs. The recognition of the significance of PAF in mammalian reproduction is fascinating and may lead to new clinical applications of PAF antagonists. It appears probable that, like eicosanoids, PAF is involved in a great variety of membrane-dependent processes that play a fundamental role in the maintenance of homeostasis. PAF research has provided several potent natural and synthetic antagonists which may facilitate the clinical application of these drugs in the near future.
abstract_unstemmed	Summary This review is an attempt to summarise recent data on platelet activating factor (PAF) and PAF antagonists from 1988 to the present. This period saw a burst in research activity focused predominantly on the effect of PAF in various organs. The effect of PAF and its antagonists was further intensively studied in vitro on isolated platelets, leucocytes, macrophages and endothelial cells. From these and earlier data, based on the catastrophe theory of Thorn and Zeeman, a new concept on the interaction between PAF and various cytokines could be recognised as an important mechanism of action of the phospholipid mediator, suggesting the existence of an autocatalytic feedback network through which PAF can influence cellular function under certain pathophysiological conditions. This mechanism can be regarded as the culmination of our recent knowledge on the role of PAF, and may influence the possible clinical implications of PAF antagonists in the near future. It is recognised that PAF is released in shock and ischaemic states, and that PAF antagonists can protect the heart and brain against ischaemic injury. Therefore, in contrast to the previous period, which was predominantly devoted to the elucidation of the role of PAF in immediate hypersensitivity reactions, studies performed on cerebral, myocardial and intestinal ischaemia as well as in various shock conditions have concentrated on entirely new aspects of the effect of PAF antagonists, emphasising the significance of the inflammatory process and cell-to-cell interactions in these pathophysiological states. This has led to a re-evaluation of the experimental data previously accumulated. At the same time, these new trends in PAF and PAF antagonist research have explored further possibilities for the application of PAF antagonists in clinical practice. Attention has been focused on the physiological role of PAF as a signal molecule, especially between the neuroendocrine system and related sensory organs. The recognition of the significance of PAF in mammalian reproduction is fascinating and may lead to new clinical applications of PAF antagonists. It appears probable that, like eicosanoids, PAF is involved in a great variety of membrane-dependent processes that play a fundamental role in the maintenance of homeostasis. PAF research has provided several potent natural and synthetic antagonists which may facilitate the clinical application of these drugs in the near future.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190
container_issue	1
title_short	Platelet Activating Factor (PAF)
url	https://dx.doi.org/10.2165/00003495-199142010-00002
remote_bool	true
author2	Hosford, David Guinot, Philippe Esanu, André Braquet, Pierre
author2Str	Hosford, David Guinot, Philippe Esanu, André Braquet, Pierre
ppnlink	320609413
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.2165/00003495-199142010-00002
up_date	2024-07-03T16:57:36.021Z
_version_	1803577832010416128
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033158266</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519202325.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1991 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00003495-199142010-00002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033158266</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00003495-199142010-00002-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.38</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Koltai, Matyas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Platelet Activating Factor (PAF)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1991</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary This review is an attempt to summarise recent data on platelet activating factor (PAF) and PAF antagonists from 1988 to the present. This period saw a burst in research activity focused predominantly on the effect of PAF in various organs. The effect of PAF and its antagonists was further intensively studied in vitro on isolated platelets, leucocytes, macrophages and endothelial cells. From these and earlier data, based on the catastrophe theory of Thorn and Zeeman, a new concept on the interaction between PAF and various cytokines could be recognised as an important mechanism of action of the phospholipid mediator, suggesting the existence of an autocatalytic feedback network through which PAF can influence cellular function under certain pathophysiological conditions. This mechanism can be regarded as the culmination of our recent knowledge on the role of PAF, and may influence the possible clinical implications of PAF antagonists in the near future. It is recognised that PAF is released in shock and ischaemic states, and that PAF antagonists can protect the heart and brain against ischaemic injury. Therefore, in contrast to the previous period, which was predominantly devoted to the elucidation of the role of PAF in immediate hypersensitivity reactions, studies performed on cerebral, myocardial and intestinal ischaemia as well as in various shock conditions have concentrated on entirely new aspects of the effect of PAF antagonists, emphasising the significance of the inflammatory process and cell-to-cell interactions in these pathophysiological states. This has led to a re-evaluation of the experimental data previously accumulated. At the same time, these new trends in PAF and PAF antagonist research have explored further possibilities for the application of PAF antagonists in clinical practice. Attention has been focused on the physiological role of PAF as a signal molecule, especially between the neuroendocrine system and related sensory organs. The recognition of the significance of PAF in mammalian reproduction is fascinating and may lead to new clinical applications of PAF antagonists. It appears probable that, like eicosanoids, PAF is involved in a great variety of membrane-dependent processes that play a fundamental role in the maintenance of homeostasis. PAF research has provided several potent natural and synthetic antagonists which may facilitate the clinical application of these drugs in the near future.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Platelet Activate Factor</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rabbit Platelet</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Platelet Activate Factor Receptor</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Platelet Activate Factor Antagonist</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tumour Necrosis Factor Secretion</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hosford, David</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guinot, Philippe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Esanu, André</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Braquet, Pierre</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Drugs</subfield><subfield code="d">Berlin [u.a.] : Springer, 1971</subfield><subfield code="g">42(1991), 1 vom: Juli, Seite 9-29</subfield><subfield code="w">(DE-627)320609413</subfield><subfield code="w">(DE-600)2021165-X</subfield><subfield code="x">1179-1950</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:42</subfield><subfield code="g">year:1991</subfield><subfield code="g">number:1</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:9-29</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00003495-199142010-00002</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.38</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">42</subfield><subfield code="j">1991</subfield><subfield code="e">1</subfield><subfield code="c">07</subfield><subfield code="h">9-29</subfield></datafield></record></collection>
score	7.4008827

Nicht das Richtige dabei?

Schreiben Sie uns!

Platelet Activating Factor (PAF)

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?